Indian pharmaceutical major Lupin Limited has entered into a licensing and supply agreement with Spain-based Galenicum Health, S.L.U. to expand the global availability of injectable Semaglutide, a key GLP-1 receptor agonist used in the treatment of Type 2 diabetes and obesity.
The agreement has been executed through Lupin’s subsidiary Lupin Atlantis Holdings SA (LAHSA). Under the terms of the partnership, Galenicum will be responsible for the development, manufacturing, and supply of finished Semaglutide formulations, while Lupin will lead regulatory filings, approvals, commercialization, and distribution across 23 countries, spanning Canada, Europe, Southeast Asia, and Latin America.
The collaboration marks a significant step in Lupin’s strategy to strengthen its presence in the rapidly expanding global GLP-1 market, as demand for diabetes and weight-management therapies continues to surge worldwide. While Lupin already has a strong footprint in anti-diabetic therapies in India and the U.S., this partnership positions the company to scale its reach beyond these markets.
Commenting on the development, Fabrice Egros, President – Corporate Development, Lupin, said the partnership represents a strategic milestone for the company’s Semaglutide portfolio. He noted that with diabetes prevalence rising globally and obesity emerging as a critical public health challenge, Semaglutide has become an essential therapy. The collaboration, he added, enables Lupin to leverage its established commercial infrastructure across multiple geographies to improve patient access to high-quality and cost-effective treatment options.
From Galenicum’s perspective, the alliance supports its ambition to become a leading B2B player in the GLP-1 space. Joaquim Domingo, Co-founder of Galenicum, said the company has made substantial investments in its GLP-1 development pipeline to address global demand. He emphasized that the partnership with Lupin would allow Galenicum to deliver scale, reliability, and competitiveness while helping transform patient care worldwide.
Semaglutide, a glucagon-like peptide-1 analogue, works by regulating blood sugar levels and appetite. It is widely prescribed for adults with Type 2 diabetes in combination with diet and exercise and is increasingly used for long-term weight management in adults with obesity or overweight conditions.
Lupin Limited, headquartered in Mumbai, operates in more than 100 markets globally with a diversified portfolio spanning branded and generic formulations, complex generics, biotechnology products, and APIs. The company has 15 manufacturing facilities, seven research centers, and a workforce of over 24,000 employees worldwide.
Galenicum, headquartered in Barcelona, Spain, markets pharmaceutical products in over 70 countries and has a strong focus on value-added generics, particularly in diabetes care and GLP-1 therapies.
The Lupin–Galenicum partnership underscores the growing global push to expand access to next-generation metabolic therapies, as pharmaceutical companies race to address the twin challenges of diabetes and obesity at scale.
